Abstract: UQCC2-based computer-assisted method, system, and device for diagnosing osimertinib-resistant lung cancer, predicting drug treatment effects, and screening drugs targeted for osimertinib-resistant lung cancer are provided. The method includes receiving input data, the input data including expression level data of UQCC2 in a patient with lung cancer; generating, based on the input data, an indication of whether the patient with lung cancer is a patient with osimertinib-resistant lung cancer through a machine learning model, a lung cancer including non-small cell lung cancer.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Disclosed are a carbon nanotube (CNT)-based three-dimensional ordered macroporous (3DOM) carbon material and a preparation method thereof. The CNT-based 3DOM carbon material comprises a honeycomb network structure having a 3DOM structure formed by overlapping CNTs, wherein ordered macropores each have a diameter of 270 nm to 360 nm, and the CNTs each have an outer diameter of 8 nm to 20 nm.

Abstract: Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: The present disclosure provides an inversion method for determining a pollution source list based on artificial intelligence and big data, an inversion system for determining the pollution source list based on artificial intelligence and big data, and applications thereof, which provides basic data support for government sectors to formulate relevant environmental protection measures. The specific technical solution employed in the present disclosure is as follows: finding out an emission source that makes the highest contribution to the pollutant concentration of any cell with an advanced 3D CNN artificial intelligence algorithm based on artificial intelligence and big data, establishing a model of the relationship between pollutant concentration and emission, and finding out the relationship between pollutant concentration and emission with machine learning technology, i.e., estimating an emission from a given pollutant concentration, and estimating a pollutant concentration from a given emission.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: A method for forming a multiwire structure having two conductive wires insulated from and bonded to each other by insulating material includes applying a first fluid coating material to a first conductive wire. The first conductive wire bearing the first fluid coating material is advanced through a first die forming a first electrically insulated conductive wire comprising a solid layer of a first insulating material on the first conductive wire. A second conductive wire is provided adjacent to the first electrically insulated conductive wire, and a second fluid coating material is applied to the second conductive wire. The first electrically insulated conductive wire and the adjacent second conductive wire bearing the second fluid coating material are then advanced through a second die to form a multiwire structure having two conductive wires electrically insulated from each other and bonded to each other by the first and second insulating materials.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

Abstract: Provided herein are USP28 inhibitors, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment and/or diagnosis.

Abstract: Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: Provided herein are GLP-1 receptor modulator compounds, pharmaceutical compositions, methods of their preparation, and methods of their use in treatment, and/or diagnosis.

Abstract: An electric motor includes a stator and a rotor rotatable relative to the stator and having an air gap between the rotor and the stator, wherein at least one of the stator and the rotor include a plurality of windings formed from ultra-conducting copper foil.

Abstract: Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.